CheckpointPresentation_CKPT_Jan2025

NASDAQ: CKPTCorporate PresentationJanuary 20252Checkpoint TherapeuticsSafe Harbor StatementThis presentation may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For such forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, any statements relating to the timing and commercial launch and availability of UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or curative radiation, the commercial potential of UNLOXCYT, and anticipated healthcare professional and patient acceptance and use of UNLOXCYT for the FDA-approved indication, the potential differentiation of UN